PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Lenalidomide
PSUR-outcome
|
01/10/2021
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Indapamide
PSUR-outcome
|
09/09/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Betamethasone dipropionate/Clotrimazol
PSUR-outcome
|
08/09/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Hydroxycarbamide
PSUR-outcome
|
08/09/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Glatiramer
PSUR-outcome
|
08/09/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Ribavirin
PSUR-outcome
|
08/09/2021
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Hydroxyzine
PSUR-outcome
|
30/08/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Baclofen
PSUR-outcome
|
30/08/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Benazepril
PSUR-outcome
|
27/08/2021
Further information and amendments to the product information in all EU languages are available on the EMA website.
Posaconazole
PSUR-outcome
|
26/08/2021
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
